Nezar Falluji, MD
Interventional Cardiology · Phoenix, AZNPI 1053427872
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 57 manufacturers reported payments, led by Penumbra, Inc. at 39.3% of the total. Reporting peaked in 2019 at $16,328 and has fallen 80.4% since, to $3,194 in 2025.
Across 603 payments — averaging $83.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$20K
- Bard Peripheral Vascular, Inc.$10K
- Edwards Lifesciences$7K
- Medtronic$4K
- Boston Scientific$1K
- Abbott$1K
- plus $7K from 51 others
Across 9 payments — averaging $33,064 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$266K
- Amgen$31K
What the payments were for
- Consulting fees$5,55011%
- Speaking & faculty fees$26,00052%
- Travel & lodging$4,1308%
- Food & beverage$14,53829%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$17,659
- LUTONIX$9,856
- PASCAL$3,304
- HawkOne$2,873
- Indigo System$2,505
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$185
- FFRangio$166
- AFFERA MAPPING SYSTEM$151
- ENROUTE Transcarotid Neuroprotection System$142
- ENROUTE Transcarotid Stent$142
- GENERAL - STENTS$141
- ENSITE$141
- Carto 3$137
- VANTAGEVIEW$127
- GENERAL - THERAPIES$123
- AMPLATZER TALISMAN$123
- LOKELMA$121
- COREVALVE EVOLUT R$115
- SYMPLICITY G3$107
- SELUTION SLR PTCA$106
How this compares
$50,253 in reported general payments places this provider in the 85th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $66,002 |
| XareltoRivaroxaban | 56 | $57,836 |
| EntrestoSacubitril/Valsartan | 27 | $39,039 |
| JardianceEmpagliflozin | 22 | $17,041 |
| BrilintaTicagrelor | 27 | $14,600 |
| Ranolazine ErRanolazine | 13 | $1,211 |
| ClopidogrelClopidogrel Bisulfate | 122 | $1,107 |
| Valsartan | 15 | $797 |
| Potassium Chloride | 27 | $511 |
| Amiodarone Hcl | 18 | $463 |
| Metoprolol Succinate | 37 | $437 |
| Carvedilol | 39 | $400 |
| Warfarin Sodium | 21 | $325 |
| Atorvastatin Calcium | 28 | $235 |
| Rosuvastatin Calcium | 16 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $599 | $66,00266 claims |
| Johnson & JohnsonXarelto | $990 | $57,83656 claims |
| NovartisEntresto | $688 | $39,03927 claims |
| Boehringer IngelheimJardiance | $53 | $17,04122 claims |
| AstraZenecaBrilinta | $316 | $14,60027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$1.1M
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Akil LoliPhoenix$160K
- Nishant GuptaPhoenix$145K
- Richard HeuserPhoenix$68K
- Ahmad JabriPhoenix$39K
- Edward EvansPhoenix$36K
- Basil Al KhatibPhoenix$33K
- Sourabh AggarwalPhoenix$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.